Health Care [ 2/12 ] | Biotechnology [ 3/73 ]
NASDAQ | Common Stock
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies.
The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers.
In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment.
Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season.
It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, TheU. S.
Department of Health and Human Services, and MSD International GmbH.
PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 25 | -0.21 Increased by +8.70% | -0.22 Increased by +4.55% |
| May 13, 25 | -0.21 Increased by +30.00% | -0.25 Increased by +14.88% |
| Mar 25, 25 | -0.21 Increased by +40.00% | -0.28 Increased by +23.64% |
| Nov 12, 24 | -0.29 Increased by +17.14% | -0.28 Decreased by -3.57% |
| Aug 13, 24 | -0.23 Increased by +37.84% | -0.34 Increased by +32.35% |
| May 15, 24 | -0.30 Increased by +6.25% | -0.37 Increased by +18.92% |
| Mar 27, 24 | -0.35 Increased by +47.76% | -0.44 Increased by +20.45% |
| Nov 14, 23 | -0.35 Decreased by -34.62% | -0.45 Increased by +22.22% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -9.43 M Decreased by -13.28% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -8.49 M Increased by +19.94% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 59.07 K Increased by +N/A% | -7.95 M Increased by +27.03% | Decreased by -13.46 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -10.73 M Increased by +1.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -8.33 M Increased by +27.80% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -10.60 M Decreased by -9.76% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -10.90 M Increased by +49.40% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.85 M Decreased by -46.13% | Decreased by N/A% Decreased by N/A% |